166 related articles for article (PubMed ID: 19629679)
1. Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis.
Sergentanis TN; Economopoulos KP
Breast Cancer Res Treat; 2010 Feb; 120(1):229-34. PubMed ID: 19629679
[TBL] [Abstract][Full Text] [Related]
2. Functional variants in cell death pathway genes and risk of pancreatic cancer.
Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
[TBL] [Abstract][Full Text] [Related]
3. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer.
Hashemi M; Eskandari-Nasab E; Fazaeli A; Rezaei H; Mashhadi MA; Arbabi F; Taheri M
Gene; 2012 Aug; 505(1):176-9. PubMed ID: 22659694
[TBL] [Abstract][Full Text] [Related]
4. The relationship of CASP 8 polymorphism and cancer susceptibility: a meta-analysis.
Ji GH; Li M; Cui Y; Wang JF
Cell Mol Biol (Noisy-le-grand); 2014 Dec; 60(6):20-8. PubMed ID: 25553350
[TBL] [Abstract][Full Text] [Related]
5. CASP8 -652 6N del polymorphism and cancer risk: a meta-analysis of 30 case-control studies in 50,112 subjects.
Zhang F; Yang Y; Guo C; Wang Y
Mutagenesis; 2012 Sep; 27(5):559-66. PubMed ID: 22513478
[TBL] [Abstract][Full Text] [Related]
6. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
7. Impact of caspase-8 (CASP8) -652 6N del and D302H polymorphisms on prostate cancer in different ethnic groups.
Zhang CD; Li HT; Liu K; Lin ZD; Peng QL; Qin X; He M; Wu H; Mo ZN; Yang XL
Asian Pac J Cancer Prev; 2014; 15(18):7713-8. PubMed ID: 25292051
[TBL] [Abstract][Full Text] [Related]
8. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk.
Han S; Lee KM; Choi JY; Park SK; Lee JY; Lee JE; Noh DY; Ahn SH; Han W; Kim DH; Hong YC; Ha E; Yoo KY; Kang D
Breast Cancer Res Treat; 2008 Jul; 110(2):387-93. PubMed ID: 17940865
[TBL] [Abstract][Full Text] [Related]
9. CAS P8 -652 6N del polymorphism and breast cancer risk: a systematic review and meta-analysis.
Li Z; Wang J; Wang F; Ma Z; Yu Z
Neth J Med; 2014 Jan; 72(1):10-6. PubMed ID: 24457433
[TBL] [Abstract][Full Text] [Related]
10. The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.
de Martino M; Haitel A; Schatzl G; Klingler HC; Klatte T
J Urol; 2013 Aug; 190(2):717-22. PubMed ID: 23313206
[TBL] [Abstract][Full Text] [Related]
11. Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis.
Hu Z; Li X; Yuan R; Ring BZ; Su L
Breast Cancer Res Treat; 2010 Apr; 120(3):705-14. PubMed ID: 19657731
[TBL] [Abstract][Full Text] [Related]
12. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer.
Chatterjee K; Williamson AL; Hoffman M; Dandara C
J Med Virol; 2011 Apr; 83(4):630-6. PubMed ID: 21328377
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.
Kuhlmann JD; Bankfalvi A; Schmid KW; Callies R; Kimmig R; Wimberger P; Siffert W; Bachmann HS
BMC Cancer; 2016 Aug; 16():618. PubMed ID: 27507139
[TBL] [Abstract][Full Text] [Related]
14. A systematic analysis of the association studies between CASP8 D302H polymorphisms and breast cancer risk.
Zhang Y; Li W; Hong Y; Wu G; He K; Liu D
J Genet; 2017 Jun; 96(2):283-289. PubMed ID: 28674227
[TBL] [Abstract][Full Text] [Related]
15. CASP8 D302H and meningioma risk: an analysis of five case-control series.
Bethke L; Sullivan K; Webb E; Murray A; Schoemaker M; Auvinen A; Kiuru A; Salminen T; Johansen C; Christensen HC; Muir K; McKinney P; Hepworth S; Dimitropoulou P; Lophatananon A; Feychting M; Lönn S; Ahlbom A; Malmer B; Henriksson R; Swerdlow A; Houlston R
Cancer Lett; 2009 Jan; 273(2):312-5. PubMed ID: 18823701
[TBL] [Abstract][Full Text] [Related]
16. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population.
Pittman AM; Broderick P; Sullivan K; Fielding S; Webb E; Penegar S; Tomlinson I; Houlston RS
Br J Cancer; 2008 Apr; 98(8):1434-6. PubMed ID: 18362937
[TBL] [Abstract][Full Text] [Related]
17. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk.
Liu B; Zhang Y; Jin M; Ni Q; Liang X; Ma X; Yao K; Li Q; Chen K
Mol Carcinog; 2010 Jan; 49(1):75-84. PubMed ID: 19795398
[TBL] [Abstract][Full Text] [Related]
18. The common D302H variant of CASP8 is associated with risk of glioma.
Bethke L; Sullivan K; Webb E; Murray A; Schoemaker M; Auvinen A; Kiuru A; Salminen T; Johansen C; Christensen HC; Muir K; McKinney P; Hepworth S; Dimitropoulou P; Lophatananon A; Feychting M; Lönn S; Ahlbom A; Malmer B; Henriksson R; Swerdlow A; Houlston R
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):987-9. PubMed ID: 18398042
[TBL] [Abstract][Full Text] [Related]
19. CASP8 -652 6N del polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis.
Peng Q; Lao X; Tang W; Chen Z; Li R; Wang J; Deng Y; Li T; Qin X; Li S
PLoS One; 2014; 9(2):e87925. PubMed ID: 24498403
[TBL] [Abstract][Full Text] [Related]
20. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases.
De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Barile M; Fortuzzi S; Ravagnani F; Pierotti MA; Radice P; Peterlongo P
Breast Cancer Res Treat; 2009 Feb; 113(3):607-8. PubMed ID: 18343995
[No Abstract] [Full Text] [Related]
[Next] [New Search]
